US 12,433,963 B2
CT contrast agent for detection of cachexia
Andrej Babic, Veigy-Foncenex (FR); and Nathalie Stransky-Heilkron, Valserhône (FR)
Assigned to UNIVERSITÉ DE GENÈVE; Adiposs SA, Geneva (CH)
Appl. No. 17/430,683
Filed by UNIVERSITÉ DE GENÈVE, Geneva (CH); and Adiposs SA, Geneva (CH)
PCT Filed Feb. 13, 2020, PCT No. PCT/EP2020/053768
§ 371(c)(1), (2) Date Aug. 12, 2021,
PCT Pub. No. WO2020/165349, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. 19157026.6 (EP), filed on Feb. 13, 2019.
Prior Publication US 2022/0160900 A1, May 26, 2022
Int. Cl. A61K 49/04 (2006.01)
CPC A61K 49/0438 (2013.01) [A61K 49/0461 (2013.01); A61K 49/0495 (2013.01)] 15 Claims
 
1. A method of diagnosing cachexia or precachexia in a subject, the method comprising the steps of:
a) orally administering a peroral contrast agent to the subject, the peroral contrast agent comprising a biocompatible formulation of an iodinated fatty acid, ester, or combinations thereof with 16 to 18 carbon atoms having the following formula I:

OG Complex Work Unit Chemistry
wherein:
n=14-16;
R1 is, at each occurrence, independently H or I, provided that when a number of iodine atoms is 1 to 6, the iodine atoms are not geminal or vicinal; and
R2 is H, unsaturated alkyls, saturated alkyls, linear alkyls, branched alkyls, alkoxyalkyl, hydroxyalkoxyalkyl, polyhydroxyalkyl, or hydroxy poly alkyleneoxyalkyl;
b) obtaining an in vivo image of brown and/or beige adipose tissue (BAT) in the subject with Computed Tomography (CT); and
c) comparing the obtained in vivo image to a CT scan of a normal subject, wherein a diagnosis of cachexia or precachexia is performed by:
i) establishing positive or increased enhancement of BAT and/or beige adipose tissue; or
ii) detecting a white adipose tissue (WAT) browning and/or BAT activity in the subject.